https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50840 Wed 28 Feb 2024 16:33:00 AEDT ]]> Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49984 Wed 28 Feb 2024 15:55:05 AEDT ]]> Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54560 Thu 29 Feb 2024 10:27:50 AEDT ]]> Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45364 Thu 27 Oct 2022 15:35:45 AEDT ]]> Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46923 Thu 08 Dec 2022 09:09:54 AEDT ]]> Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46276 Mon 14 Nov 2022 15:31:11 AEDT ]]> Mepolizumab effectiveness and identification of super-responders in severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]>